Home / Resource Library / Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Results of a study investigating Tenalisib for treatment of relapsed T-cell lymphomas.